Liu Yang, Liu Zhaocen
Department of Stomatology, The Affiliated People's Hospital of Ningbo University, Ningbo City, Zhejiang, 315100, China.
Department of Prosthodontics, Ningbo Stomatological Hospital Affiliated to Hangzhou Medical College, Ningbo, Zhejiang, 315000, China.
In Vitro Cell Dev Biol Anim. 2025 Jun 17. doi: 10.1007/s11626-025-01032-3.
Protein kinase Cβ (PRKCB) is expressed in THP-1 cells and has been found upregulated in periodontitis. Exploring the specific molecular mechanisms that promote the osteogenic differentiation of human periodontal ligament stem cells (hPDLSCs) is beneficial to optimizing periodontal regeneration. THP-1 cells were induced to differentiate into macrophages, and the levels of PRKCB in macrophages with different phenotypes were examined, including PKC activity. The effect of pg-LPS induction on osteogenic differentiation of hPDLSCs was measured by measuring alkaline phosphatase, osteocalcin, osteogenic-related proteins, and mineralized nodules. Ruboxistaurin, an inhibitor of PRKCB, was used to treat M1 macrophages to examine its effect on macrophage polarization. Additionally, the cascade effect of ruboxistaurin on osteogenic differentiation was investigated by co-incubating hPDLSCs with medium from macrophages. The results indicated that PRKCB upregulation and increased PKC activity were induced in M1 macrophages upon stimulation with LPS/IFN-γ. pg-LPS resulted in decreased levels of osteogenic-related genes in hPDLSCs, accompanied by a decrease in mineralized nodules. PRKCB inhibitor reduced PKC activity, inhibited macrophage M1 polarization, and reduced M1-related inflammatory cytokine secretion. Exposure of hPDLSCs to M1 macrophage-derived conditioned medium impaired their osteogenic differentiation potentials, which was significantly attenuated by pretreatment of M1 macrophages with ruboxistaurin. Together, inhibition of PRKCB suppressed inflammatory M1 macrophage polarization, thus attenuating M1 macrophage-induced impairment in the osteogenic differentiation of hPDLSCs. These results provide a theoretical and scientific basis for optimizing the potential clinical application of hPDLSC therapy in periodontal regeneration.
蛋白激酶Cβ(PRKCB)在THP-1细胞中表达,且已发现在牙周炎中上调。探索促进人牙周膜干细胞(hPDLSCs)成骨分化的具体分子机制,有利于优化牙周组织再生。将THP-1细胞诱导分化为巨噬细胞,检测不同表型巨噬细胞中PRKCB的水平,包括PKC活性。通过检测碱性磷酸酶、骨钙素、成骨相关蛋白和矿化结节,来测定pg-LPS诱导对hPDLSCs成骨分化的影响。使用PRKCB抑制剂鲁伯斯塔林处理M1巨噬细胞,以检测其对巨噬细胞极化的影响。此外,通过将hPDLSCs与巨噬细胞培养基共同孵育,研究鲁伯斯塔林对成骨分化的级联效应。结果表明,LPS/IFN-γ刺激可诱导M1巨噬细胞中PRKCB上调和PKC活性增加。pg-LPS导致hPDLSCs中成骨相关基因水平降低,同时矿化结节减少。PRKCB抑制剂降低了PKC活性,抑制了巨噬细胞M1极化,并减少了M1相关炎性细胞因子的分泌。hPDLSCs暴露于M1巨噬细胞来源的条件培养基会损害其成骨分化潜能,而用鲁伯斯塔林预处理M1巨噬细胞可显著减弱这种损害。总之,抑制PRKCB可抑制炎性M1巨噬细胞极化,从而减轻M1巨噬细胞对hPDLSCs成骨分化的诱导损伤。这些结果为优化hPDLSC疗法在牙周组织再生中的潜在临床应用提供了理论和科学依据。